Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial

• Hoofdauteurs: L. L. Engmann (Auteur), B. S. Maslow (Auteur), L. A. Kaye (Auteur), D. W. Griffin (Auteur), A. J. DiLuigi (Auteur), D. W. Schmidt (Auteur), D. R. Grow (Auteur), J. C. Nulsen (Auteur), C. A. Benadiva (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2019-01-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background Ovarian hyperstimulation syndrome remains a serious complication during in vitro fertilization cycles if high dose human chorionic gonadotropin (hCG) is used to trigger ovulation in high responder patients. Though much of this risk is mitigated with trigger using gonadotropin rel...